Oramed Pharmaceuticals (ORMP +1%) gains after receiving approval for a key patent by the Japanese Patent Office. The patent, which has also been approved in Israel and Australia, is titled "Methods and Compositions for Oral Administrations of Proteins," and covers a core concept of the company's technology. ORMP's portfolio now consists of seven issued patents with 28 patents pending.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs